In TRACERx, CHIP mutations were observed in 34% (143/421) of patients with early-stage treatment-naïve NSCLC (Table 1 and Fig S1), with a 5% median VAF (interquartile range [IQR] 2.9-11%), most commonly affecting DNMT3A, TET2, and ASXL1. This evidence concerns the gene TET2 and non-small cell lung carcinoma.